Department of Hematology and Rheumatology, Kagoshima University.
J Clin Exp Hematop. 2023 Mar 28;63(1):1-11. doi: 10.3960/jslrt.22034. Epub 2023 Jan 30.
Several prognostic indices have been reported for peripheral T-cell lymphoma (PTCL) and adult T-cell leukemia/lymphoma (ATL). The clinical features and prognosis of PTCL differ in a specified pathological diagnosis, whereas those of ATL are more diverse, even in the same clinical subtypes of acute, lymphoma, chronic, and smoldering. The establishment of a prognostic index is important not only for a risk-stratified treatment approach, but also for the preliminary evaluation of therapeutic findings by novel modalities, particularly in rare and aggressive diseases such as ATL. Five prognostic indices for PTCL-not otherwise specified and 6 prognostic indices for ATL are discussed herein. Recent advances in molecular analyses have facilitated prognostication using molecular profiles. In addition to the external validation of these prognostic indices, which are mostly established by clinical information, the development of novel indices by incorporating molecular profiles is warranted to improve the outcomes of patients through the selection of optimal treatments.
已经有报道称,外周 T 细胞淋巴瘤(PTCL)和成人 T 细胞白血病/淋巴瘤(ATL)有多种预后指标。PTCL 的临床特征和预后因特定的病理诊断而有所不同,而 ATL 的临床特征则更为多样化,即使是在相同的临床亚型(急性、淋巴瘤、慢性和亚临床)中也是如此。建立预后指标不仅对风险分层治疗方法很重要,而且对新型治疗方式的治疗结果进行初步评估也很重要,特别是在罕见和侵袭性疾病(如 ATL)中。本文讨论了 5 种用于非特指性 PTCL 的预后指标和 6 种用于 ATL 的预后指标。分子分析的最新进展使得利用分子谱进行预后预测成为可能。除了对这些主要基于临床信息建立的预后指标进行外部验证外,通过纳入分子谱来开发新的预后指标,也有必要通过选择最佳治疗方法来改善患者的预后。